Few Canadians Aware Of Peripheral Arterial Disease Clogged Arteries In The Legs
Two out of three Canadians are not aware of peripheral arterial disease (P.A.D.), a common vascular disease that affects as many as 800,000 Canadians, according to a study published in the Canadian Journal of Cardiology. Commonly known as "hardening of the arteries," P.A.D. occurs when arteries in the legs become narrowed or clogged with fatty deposits, reducing blood flow to the legs. As a result, P.A.D.
Using Atypical Antipsychotics Increases Risk Of Sudden Cardiac Death In Adults
Patients ages 30 to 74 who took atypical antipsychotics such as risperidone (sold as Risperdal), quetiapine (Seroquel), olanzapine (Zyprexa) and clozapine (Clozaril) had a significantly higher risk of sudden death from cardiac arrhythmias and other cardiac causes than patients who did not take these medications, according to a new study funded by HHS' Agency for Healthcare Research and Quality. The risk of death increased with higher doses of the drugs taken.
Saturday, January 17, 2009
Few Canadians Aware Of Peripheral Arterial Disease Clogged Arteries In The Legs
Few Canadians Aware Of Peripheral Arterial Disease Clogged Arteries In The Legs
Two out of three Canadians are not aware of peripheral arterial disease (P.A.D.), a common vascular disease that affects as many as 800,000 Canadians, according to a study published in the Canadian Journal of Cardiology. Commonly known as "hardening of the arteries," P.A.D. occurs when arteries in the legs become narrowed or clogged with fatty deposits, reducing blood flow to the legs. As a result, P.A.D.
Using Atypical Antipsychotics Increases Risk Of Sudden Cardiac Death In Adults
Patients ages 30 to 74 who took atypical antipsychotics such as risperidone (sold as Risperdal), quetiapine (Seroquel), olanzapine (Zyprexa) and clozapine (Clozaril) had a significantly higher risk of sudden death from cardiac arrhythmias and other cardiac causes than patients who did not take these medications, according to a new study funded by HHS' Agency for Healthcare Research and Quality. The risk of death increased with higher doses of the drugs taken.
Two out of three Canadians are not aware of peripheral arterial disease (P.A.D.), a common vascular disease that affects as many as 800,000 Canadians, according to a study published in the Canadian Journal of Cardiology. Commonly known as "hardening of the arteries," P.A.D. occurs when arteries in the legs become narrowed or clogged with fatty deposits, reducing blood flow to the legs. As a result, P.A.D.
Using Atypical Antipsychotics Increases Risk Of Sudden Cardiac Death In Adults
Patients ages 30 to 74 who took atypical antipsychotics such as risperidone (sold as Risperdal), quetiapine (Seroquel), olanzapine (Zyprexa) and clozapine (Clozaril) had a significantly higher risk of sudden death from cardiac arrhythmias and other cardiac causes than patients who did not take these medications, according to a new study funded by HHS' Agency for Healthcare Research and Quality. The risk of death increased with higher doses of the drugs taken.
Friday, January 16, 2009
St. Jude Medical Announces Japanese Approval Of Atlas II ICD
St. Jude Medical, Inc. (NYSE:STJ) today announced regulatory approval from the Japanese Ministry of Health, Labour and Welfare (MHLW), in addition to reimbursement approval, of its Atlas® II implantable cardioverter defibrillator (ICD), a device used to treat patients with potentially lethal abnormal heart rhythms. More at...
St. Jude Medical, Inc. (NYSE:STJ) announced the publication of results from the landmark FAME (Fractional flow reserve (FFR) vs. Angiography in Multivessel Evaluation) study that demonstrate a statistically significant 30 percent difference in Major Adverse Cardiac Events (MACE) such as death, myocardial infarction and repeat revascularization. More at...
Phoenix, AZ - Zila Pharmaceuticals, Inc., a division of Zila, Inc. (NASDAQ GM: ZILA) and marketer of the ViziLite® Plus with TBlue® system for the early detection of oral abnormalities that could lead to cancer, has been honored with two awards from Hygienetown, the magazine and web community for dental hygienists. More at...
Royal Philips Electronics (NYSE: PHG, AEX: PHI) and Hansen Medical, Inc. (Nasdaq: HNSN) today announced that they have signed joint development and cooperation agreements to co-develop integrated products that may simplify complex cardiac procedures to diagnose and treat irregular heartbeats, also known as arrhythmias. Cardiac arrhythmias can drastically reduce the quality of life and can also lead to serious health risks including heart failure and stroke. More at...
The first patient receiving focal preventive treatment for vulnerable plaque recently underwent a 6-month follow-up examination that revealed successful stabilization of the target plaque. The interventional cardiology team led by Professor Patrick W. Serruys, MD, PhD, of Erasmus University, placed a vProtect(TM) Luminal Shield in the left anterior descending (LAD) coronary artery of the patient at Erasmus Medical Center in Rotterdam in June of 2008. More at...
Hansen Medical, Inc. (NASDAQ: HNSN) will showcase its Sensei(R) Robotic Catheter System and the CoHesion(TM) 3-D Visualization Module here at the 14th Annual Boston Atrial Fibrillation Symposium, Jan. 15-17, 2009. The integrated electrophysiology (EP) solution offers physicians a software interface between Hansen Medical's robotic catheter system and St. Jude Medical's EnSite(TM) System advanced mapping technology. More at...
St. Jude Medical, Inc. (NYSE:STJ) announced the publication of results from the landmark FAME (Fractional flow reserve (FFR) vs. Angiography in Multivessel Evaluation) study that demonstrate a statistically significant 30 percent difference in Major Adverse Cardiac Events (MACE) such as death, myocardial infarction and repeat revascularization. More at...
Phoenix, AZ - Zila Pharmaceuticals, Inc., a division of Zila, Inc. (NASDAQ GM: ZILA) and marketer of the ViziLite® Plus with TBlue® system for the early detection of oral abnormalities that could lead to cancer, has been honored with two awards from Hygienetown, the magazine and web community for dental hygienists. More at...
Royal Philips Electronics (NYSE: PHG, AEX: PHI) and Hansen Medical, Inc. (Nasdaq: HNSN) today announced that they have signed joint development and cooperation agreements to co-develop integrated products that may simplify complex cardiac procedures to diagnose and treat irregular heartbeats, also known as arrhythmias. Cardiac arrhythmias can drastically reduce the quality of life and can also lead to serious health risks including heart failure and stroke. More at...
The first patient receiving focal preventive treatment for vulnerable plaque recently underwent a 6-month follow-up examination that revealed successful stabilization of the target plaque. The interventional cardiology team led by Professor Patrick W. Serruys, MD, PhD, of Erasmus University, placed a vProtect(TM) Luminal Shield in the left anterior descending (LAD) coronary artery of the patient at Erasmus Medical Center in Rotterdam in June of 2008. More at...
Hansen Medical, Inc. (NASDAQ: HNSN) will showcase its Sensei(R) Robotic Catheter System and the CoHesion(TM) 3-D Visualization Module here at the 14th Annual Boston Atrial Fibrillation Symposium, Jan. 15-17, 2009. The integrated electrophysiology (EP) solution offers physicians a software interface between Hansen Medical's robotic catheter system and St. Jude Medical's EnSite(TM) System advanced mapping technology. More at...
Subscribe to:
Posts (Atom)
